| Oct 17 |
Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
|
| Oct 16 |
Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
|
| Oct 9 |
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
|
| Sep 27 |
High Growth Tech Stocks To Watch In September 2024
|
| Sep 27 |
Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?
|
| Sep 25 |
Zai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025
|
| Sep 17 |
Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
|
| Aug 29 |
Zai Lab Limited (ZLAB): Top ADR Stock According to Hedge Funds
|
| Aug 22 |
Zai Lab Announces Participation in September Investor Conferences
|
| Aug 17 |
Zai Lab Limited (NASDAQ:ZLAB) institutional owners may be pleased with recent gains after 25% loss over the past year
|
